EnCompass receives FDA conditional IDE approval to commence a US pilot study of its F2 cerebral embolic protection (CEP) system in patients undergoing transcatheter aortic valve replacement (TAVR)

Posted on by

EnCompass plans to immediately initiate clinical site start-up activities in the US CARSON CITY, Nev., Sept. 27, 2023 /PRNewswire/ — EnCompass Technologies, Inc., a privately held medical device company focused on protecting patients from brain injury during cardiovascular procedures,…